Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Treatment options for Ph+ ALL

Oliver Ottmann • 3 Jul 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies BiTEs Blinatumomab Dasatinib Imatinib Nilotinib Ponatinib

Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, discusses the efficacy and drawbacks of tyrosine kinase inhibitors (TKIs) as a potential treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Oliver Ottmann

3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann • 3 Jul 2020
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
3:07
How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann • 3 Jun 2020
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al. • 17 May 2019

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals